Struthers Report V27 #8.10 Salt and Graphite, SALT, NGC, TAAT, FDA approves J&J booster Oct. ,16, 2021

Know when to hold-em!
Know when to fold-em!
Know where to set stops!
Know when to run!
Never count your portfolio
Until the sells are done..

rhstruthers@gmail.com ***519-374-9332*** ***Monthly subscription US$19.99***

You may have noticed, I have not put out a new pick in a while as this is the 10th update since the last pick. I don't put out new picks for the sake of something new in a crappy market. I think this crap market is bottoming out, but I want to see some more proof. There are a few things happening and the odd stock here and there that is doing well. Fortunately we have some of them. Gold pulled back Friday but copper has popped higher this week from about $4.30 to $4.70.

Northern Graphite TSXV:NGC OTC:NGPHF Recent Price - $0.51
Entry Price $0.50 Opinion – strong buy on this break out

The stock broke out on the chart a few days ago. NGC has one of the best undeveloped graphite deposits in the world, and deposits like this will be absolutely necessary if there is any seriousness to move into green energy. There is a big push to go electric and NGC will benefit. The company has started an awareness campaign that highlights the challenges and needs to go more electric. The main points:

- The substantial number of new graphite mines that are needed to meet projected demand;
- Long and insecure supply chains that are subject to political interference and unpredictable events such as the current turmoil in shipping markets;
- ESG issues relating to the production of natural and synthetic graphite and their conversion to battery anode material.

The stock broke decisively over the last high and is probably headed to test the $0.70 area.

Atlas Salt TSXV:SALT Recent Price - $1.06
Entry Price - $0.80 Opinion – strong buy

SALT also broke out on the chart Friday with feasibility news, **seismic data for the project has favourably impacted the strategy for coming drilling**, which will help determine mining methodology.

Highlights:

- Based on seismic information for the homogeneous and high-grade Great Atlantic deposit, the drill program will step out **500 metres toward the deepwater port** from the existing northernmost hole (CC-4) drilled by the company, which returned **335.3 metres grading 96.8 per cent sal**t starting only 190 metres downhole. The top 125 metres of that intercept graded 98 per cent salt (National Instrument 43-101 Apex Resource estimate report, 2016). The new stepout hole will be collared approx. 3.5 kms from the port in an area where seismic data suggest that the deposit thickens.
- One of the key issues being addressed by the feasibility study is whether the deposit can be accessed through an inclined ramp or a vertical shaft. Ramp access is anticipated to require less capital and operating costs while providing infrastructure efficiency.
- Full permitting have been received from the Newfoundland and Labrador government for the Atlas drill program designed to acquire geotechnical data and further delineate the deposit.

Rowland Howe, president of Atlas, commented: "*Having managed Goderich into the largest underground salt mine in the world and after six months of guiding this project, I'm more confident than ever in describing Great Atlantic as a very advantaged asset. This deposit has all the right attributes, including the necessary infrastructure surrounding it, in one of the best locations in the world for mining. We envision an environmentally friendly salt factory with straightforward, chemical-free processing using state-of-the-art technology given the apparent predictable homogeneous nature of this deposit,*" Mr. Howe continued. "*The core from the northernmost hole is exceptional in grade and consistency and we look forward to following up on this result shortly".*

The stock broke above resistance around $1.04/05 and is likely headed to test $1.35

TAAT Global CSE:TAAT Recent Price - $3.95
Entry Price - $4.25 Opinion - buy

The company sales growth is going very very well and it looks like this company good eventually achieve a valuation in comparison to major tobacco and marijuana companies.

In regards to this growth, TAAT put this news out Friday. Over the past 60 days, TAAT Global Alternatives Inc. has secured 19 new relationships with U.S. wholesalers to carry TAAT, **adding distribution in new states** such as Virginia (population 8.5 million), Oregon (population 4.2 million) and Missouri (population 6.1 million). In a press release dated August 17, 2021 , the Company announced that it had obtained distribution in seven new U.S. states (AL, CA, FL, GA, IL, MI, MS) in just two months, and announced shortly thereafter in a press release dated September 24, 2021 that the count of TAAT retailers across the country **officially surpassed the 1,000-store mark. Just three weeks later, the Company has confirmed that more than 1,200 stores in the United States now carry TAAT** at retail. An interactive store finder map of TAAT retailers can be found on the Company's TryTAAT portal at the following link (must be 21+):

https://trytaat.com/pages/sca-store-locator

In addition to TAAT being available for purchase by the majority of smokers aged 21+ in the United States through e-commerce, the Company is also undertaking its first international launches in markets to include Australia, as well as the United Kingdom and Ireland (for which a 43,000-pack shipment landed in late September 2021).

On the chart we have a rising trend of higher lows, but the $5.00 resistance is the key level to over come. I expect the stock is heading back up there. Not a perfect doji candlestick but close enough to call this strong reversal pattern. The stock is below our original entry price and a good buy here.

It's amazing as it use to take several years for FDA to approve anything and now with these Covid shots, they get approved in months. I first saw the news on a UK news site here, that the FDA approved J&J's booster shot.

Last month, J&J said a second shot given about two months after the first increased effectiveness to 94 percent against symptomatic disease. This compares to 70 percent protection seen with a single dose. J&J published details of three studies examining different aspects of its vaccine.

The first study was a Phase III two-dose trial of up to 30,000 participants looking at the effectiveness of a second dose given 56 days after the first in adults 18 and older.

The first study found that a booster shot was 94 percent effective against symptomatic COVID-19 in the U.S. and 100 percent effective against critical illness **at least 14 days post-vaccination.**

I also reviewed J&J's press release.

There are some obvious questions. This was given an Emergency Use Authorization (EAU). How can it be an emergency if the first dose works so well? In the JNJ press release they said the single shot showed strong and long lasting protection. *"There was no evidence of reduced effectiveness over the study duration, including when the Delta variant became dominant in the U.S*." The study period was about 5 months, March to late July 2021. Oh, I know the answer, think all the $$ they make on a booster shot. J&J says their shot does not lose any effectiveness to the Delta variant – **that contradicts the main stream narrative.**

Again they use very short time periods for the results after the booster shot, **just 14 days**, but looking at the press release t**hey also reported at 28 days**. How can much be proven if something works if you measure just 14 days or 28 days. Covid-19 goes in cycles and you could easily be in a low cycle within your 14 or 28 day period. 14 days after a dose, your risk is you have a different problem other than Covid-19.

Then I looked at the actual study and this should alarm you. **First off J&J funded the study. Second is the Conflict of interest**

Dr. Polinski, Mr. Weckstein, Dr. Batech, Ms. Kabelac and Dr. Rassen are employees of and own stock options or equity in Aetion, a software-enabled healthcare analytics company. Dr. Kamath, Mr. Harvey, Mr. Jain and Dr. Khan are employees of Janssen R&D, the manufacturer of the studied vaccine Ad26.COV2.S. Dr. Schneeweiss (ORCID# 0000-0003-2575-467X) is participating in investigator-initiated grants to the Brigham and Women's Hospital from Boehringer Ingelheim unrelated to the topic of this study. He is a consultant to Aetion Inc.

So here you have all the Doctors/Scientists conducting the study have financial interest in Johnson and Johnson and/or Aetion that is a partner to all the big pharma companies and provided the study analysis.

They did not use people or patients in the study, but instead used US insurance claims data. And by the way, you cannot see that data because it is private patient information. Trust us, we are going to make a shit load of money.

The study relied on their cohort groups to submit insurance claims. This is a cut and paste from the study: "Given the expedited national vaccination effort, a sizable proportion of COVID-19 vaccinations were administered by employers, mass vaccination sites, pharmacies, and other settings where often no health insurance claims were submitted."

How the FDA can approve a so called vaccine based on insurance claim study, funded by the drug company and all the doctors/scientists having a financial interest in an approved outcome, is absurd. I went through the study and lots of poor quality info because it is relying on insurance claims. **Once again, no peer review.** If you have not figured out that the FDA is in the back pocket of big pharma, wake up. No wonder two top execs at the FDA recently resigned.

Here is Johnson and Johnson stock chart. I guess a recent $180 high is not enough for them.

All forecasts and recommendations are based on opinion. Markets change direction with consensus beliefs, which may change at any time and without notice. The author/publisher of this publication has taken every precaution to provide the most accurate information possible. The information & data were obtained from sources believed to be reliable, but because the information & data source are beyond the author's control, no representation or guarantee is made that it is complete or accurate. The reader accepts information on the condition that errors or omissions shall not be made the basis for any claim, demand or cause for action. Because of the ever-changing nature of information & statistics the author/publisher strongly encourages the reader to communicate directly with the company and/or with their personal investment adviser to obtain up to date information. Past results are not necessarily indicative of future results. Any statements non-factual in nature constitute only current opinions, which are subject to change. The author/publisher may or may not have a position in the securities and/or options relating thereto, & may make purchases and/or sales of these securities relating thereto from time to time in the open market or otherwise. Neither the information, nor opinions expressed, shall be construed as a solicitation to buy or sell any stock, futures or options contract mentioned herein. The author/publisher of this letter is not a qualified financial adviser & is not acting as such in this publication.